Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
Authors:
- 1 July 1996
- journal article
- clinical trial
- Published by Springer Nature in Calcified Tissue International
- Vol. 59 (1) , 6-11
Abstract
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years. Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density. They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo. Compared with placebo, daily intranasal calcitonin resulted in no significant bone loss in the lumbar spine, as assessed by dual photon absorptiometry, over the 2-year study period(P < 0.02). In this group, women more than 5 years postmenopause, with the lowest baseline bone mass, showed the greatest response to this treatment, with a total increase placebo in lumbar spine BMD of 3.1%. Significant spinal bone loss(P < 0.005) occurred in women receiving either placebo or thrice-weekly calcitonin. Although the rates of bone loss in the proximal femur were not significantly different in the three groups, there were differences over time. Whereas bone loss in the daily calcitonin group was insignificant, women who received placebo or thrice-weekly calcitonin experienced significant bone loss(P < 0.001). No significant changes in biochemical markers were observed in any group. Therapy was well tolerated and there were no significant treatment-related adverse events. We conclude that intranasal SCT 200 IU daily is effective and safe for the prevention of bone loss in postmenopausal women with reduced bone mass.Keywords
This publication has 16 references indexed in Scilit:
- Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.BMJ, 1992
- Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.BMJ, 1992
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSISClinical Endocrinology, 1989
- CALCITONIN FOR PREVENTION OF POSTMENOPAUSAL BONE LOSSThe Lancet, 1988
- Is there any place for salmon calcitonin in prevention of postmenopausal bone loss?Gynecological Endocrinology, 1988
- Modified Method of Spinal Computed Tomography for Trabecular Bone Mineral MeasurementsJournal of Computer Assisted Tomography, 1986
- FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASEThe Lancet, 1984
- Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal femalesEuropean Journal of Clinical Investigation, 1980
- LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGENThe Lancet, 1976